Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can eribulin slow advanced cervical cancer? new trial results are in.

NCT ID NCT01676818

Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a chemotherapy drug called eribulin in 32 people with advanced or recurrent cervical cancer that had spread or come back. The goal was to see how long the drug could keep the cancer from growing and to check for side effects. Participants had already received up to one prior chemotherapy treatment. The results help doctors understand if eribulin is a useful option for controlling this type of cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

32 people

The number who actually took part.

Started

Aug 2012

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of invasive cervical cancer * Measurable disease * 0-1 prior chemotherapy regimens for recurrent or advanced disease; platinum based chemotherapy administered as a radiation sensitizer agent is allowed and does not count as prior therapy * Absolute granulocyte count (AGC) \>= 1,500 * Platelet \>= 100,000 * Serum creatinine \< 2.0 mg/dl * Bilirubin =\< 1.5 times the upper limit of the normal range (ULN) * Alkaline phosphatase =\< 3 x ULN (in the case of liver metastases, =\< 5 x ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (in the case of liver metastases, =\< 5 x ULN) * Peripheral neuropathy grade 0-2 * Recovery of all chemotherapy or radiation-related toxicities to grade =\< 1, except for alopecia and peripheral neuropathy * Performance status 0-2 * Signed informed consent Exclusion Criteria: * Prior treatment with eribulin * Chemotherapy, radiation, or biological or targeted therapy within 3 weeks * Hormonal therapy within 1 week * Any investigational drug within 4 weeks * Known brain metastases, unless previously treated and asymptomatic for 3 months and not progressive in size or number for 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent cervical cancer Stage IIIA cervical cancer Stage IIIB cervical cancer Stage IVA cervical cancer Stage IVB cervical cancer

Contacts and locations

Locations

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.